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Abstract
Background: Blinding is the process of keeping treatment assignment hidden and is used to minimise the possibility of
bias. Trials at high risk of bias have been shown to report larger treatment effects than low-risk studies. In dermatology, one
popular method of blinding is to have independent outcome assessors who are unaware of treatment allocation assessing
the endpoint using digital photographs. However, this can be complex, expensive and time-consuming. The objective of
this study was to compare the effect of blinded and unblinded outcome assessment on the results of the STOP GAP trial.
Methods: The STOP GAP trial compared prednisolone to ciclosporin in treating pyoderma gangrenosum. Participants’
lesions were measured at baseline and at 6 weeks to calculate the primary outcome, speed of healing. Independent
blinded assessors obtained measurements from digital photographs using specialist software. In addition, unblinded
treating clinicians estimated lesion area by measuring length and width. The primary outcome was determined using
blinded measurements where available, otherwise unblinded measurements were used (method referred to as trial
measurements).
In this study, agreement between the trial and unblinded measurements was determined using the intraclass correlation
coefficient (ICC). The STOP GAP trial’s primary analysis was repeated using unblinded measurements only. We introduced
differential and nondifferential error in unblinded measurements and investigated the effect on the STOP GAP trial’s
primary analysis.
Results: Eighty-six (80%) of the 108 patients were assessed using digital images. Agreement between trial and unblinded
measurements was excellent (ICC = 0.92 at baseline; 0.83 at 6 weeks). There was no evidence that the results of the trial
primary analysis differed according to how the primary outcome was assessed (p value for homogeneity = 1.00).
Conclusions: Blinded digital image assessment in the STOP GAP trial did not meaningfully alter trial conclusions compared
with unblinded assessment. However, as the process brought added accuracy and credibility to the trial it was considered
worthwhile.
These findings question the usefulness of digital image assessment in a trial with an objective outcome and where bias is
not expected to be excessive. Further research should investigate if there are alternative, less complex ways of
incorporating blinding in clinical trials.
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Background
Blinding is the process of keeping treatment assignment
hidden after allocation and is used to minimise the
possibility of selection, performance and detection biases
[1–4]. For this reason, it is considered to be best practice
in clinical trial design [5, 6]. A lack of blinding is recog-
nised as a limitation and several issues can arise. If
participants are aware of their treatment assignment,
their response to subjective outcome measures and co-
operation may be influenced, for example when com-
pleting a questionnaire [1, 7, 8]. Participants receiving a
new intervention may have raised expectations or appre-
hensions, whilst those receiving standard care may feel
relieved or disappointed [1, 8]. An example of perform-
ance bias would be unblinded clinicians monitoring
participants on a new treatment more closely, or trans-
ferring their attitudes about either treatment to the par-
ticipants. Outcome assessors who are not blinded to
treatment allocation may report biased outcomes if they
favour a particular intervention, resulting in detection
bias. However, this situation is reduced when assessing
objective outcomes [1, 7, 8].
Once bias has been introduced in a trial, no analytical
techniques can be implemented to reverse its effects. In-
sufficiently blinded trials have been shown to report lar-
ger treatment estimates than blinded studies [9]; a
systematic review of 1346 randomised controlled trials
(RCTs) found that unblinded trials overestimated the
treatment effect by 25% when the outcome was subject-
ive and by 9% when the outcome was objective [10]. A
recent Cochrane review by Ndounga Diakou et al. [11]
suggested that open-label trials could benefit from
blinded outcome assessment to avoid detection bias. In
dermatology, the use of digital photographs to assess
outcomes is becoming increasingly popular due to the
visibility of disease on the skin’s surface and has been
used in several RCTs [9, 12, 13]. Digital images can be
sent for assessment to external individuals who have no
knowledge of treatment allocation, thus introducing a
level of blinding and potentially preventing differential
outcome assessment. Additionally, the same assessment
team can be used throughout, ensuring consistency.
However, digital photography as a means of outcome
assessment can add a layer of complexity to a trial and
comes with its own limitations. Purchasing the equip-
ment and software required can be expensive, although
cost has decreased recently with the increasing availabil-
ity of technology [1]. The process can also be time-
consuming. Digital images are often required to adhere
to a specific set of regulations to ensure consistency, and
these are then processed or reformatted for use in image
analysis software. Furthermore, images of insufficient
quality may need to be retaken, and additional resource
must be allocated to the training of clinicians to enable
them to take and process the photos in a correct and con-
sistent manner [1, 6]. Similarly, independent assessors
require training to utilise image-assessment software.
The objective of this study was to investigate what
effect independent, blinded digital image assessment had
on the primary outcome of the STOP GAP (Study of
Treatments fOr Pyoderma GAngrenosum Patients) trial
and to establish whether it offered any protection against
detection bias.
Methods
The STOP GAP trial
STOP GAP was a multicentre, parallel-group RCT
which evaluated the safety and efficacy of the two most
commonly used systemic treatments, prednisolone and
ciclosporin, in treating pyoderma gangrenosum (PG), a
painful, ulcerating skin condition. The primary outcome
was speed of healing over 6 weeks for a single target le-
sion and was chosen as previous work in patients with
venous leg ulcers suggested this was a good surrogate
for subsequent healing [14]; the STOP GAP trial team’s
justification for the use of speed of healing as the pri-
mary outcome is given here [15]. The target lesion was
identified as being ‘the largest lesion that could be
photographed on a single plane’ [13]. The protocol and
main results for the STOP GAP trial have been de-
scribed in detail elsewhere [13, 16]. The trial concluded
there was no difference in speed of healing between the
two treatments, with an adjusted difference in means of
0.003 (p = 0.97, 95% CI −0.20 to 0.21).
Digital images and assessment methods
Participants visited a clinic at baseline, at 2 and
6 weeks’ follow-up, and when the lesion had healed
(up to a maximum of 6 months). At each visit a clin-
ician measured the lesion’s maximum perpendicular
width and maximum longitudinal length; the lesion
area was then estimated using the formula: length
(cm) × width (cm) × 0.785, which approximates to the
area of an ellipse (method referred to as unblinded
measurements).
It was not possible for clinicians or participants to be
blinded due to the noticeable differences in appearance,
dosing schedule and side-effect profile of the two drugs.
For this reason, digital photographs were taken of the le-
sion at baseline and at 6 weeks and were evaluated by
two independent, blinded assessors.
The two assessors were administrators working for
the University of Nottingham within the Centre of
Evidence Based Dermatology, and their only involve-
ment in the trial was carrying out the digital image
assessment. They were trained by a consultant derma-
tologist (FEC) and had to work through a series of
training images and judged to be competent before
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being able to undertake assessment of images for the
trial. The assessors had a set protocol to follow and
carried out their assessments separately, without
knowledge of treatment allocation.
Clinicians were asked to take four photographs of
the target lesion at each visit. A target plate was
photographed next to the lesion as a point of refer-
ence for calibration in the image analysis software
(Fig. 1). Photographs were sent to Nottingham Clin-
ical Trials Unit where the best image from each visit
was chosen by the trial manager (EJM), who was also
blinded to treatment allocation. Sites were contacted
to request unsuitable photographs be retaken. Suitable
images were resized and the quality adjusted if neces-
sary. These were uploaded to the VERG Videometry
VeV (Verge Videometer) MD software (Vista Medical,
Winnipeg, MB, Canada) and the target plate was ori-
entated to 3 × 3 cm using its inner border. If orienta-
tion failed, these processing steps were repeated with
the other photographs to see if an alternative image
worked. If all images failed, the site was contacted to
request the photographs be retaken. Otherwise the as-
sessors were notified that the images were ready to
be measured.
The assessors used the VeV software to trace the
circumference of the lesion and obtain a measure-
ment of the lesion area (method referred to as
blinded measurements), which is taken to be the ‘gold
standard’ (Fig. 1). Blinded measurements may not
have been obtained for a participant if no image was
available or if the image was of poor quality and fur-
ther photographs were not available. In addition, two
dermatologists independently reviewed the images to
ensure that the lesions were consistent with a diagno-
sis of PG.
In the STOP GAP trial’s primary analysis, a mixture of
the two measurement methods was used (method re-
ferred to as trial measurements). For each participant, at
least one of the two assessors’ blinded digital measure-
ments had to be available at both baseline and 6 weeks
for that method to be used to calculate speed of healing.
If both assessors obtained measurements for an image,
the mean of the measurements was taken. For partici-
pants without blinded measurements at both baseline
and 6 weeks, their unblinded physical measurements
from both visits were used. Figure 2 illustrates this
process.
Statistical analysis
Variables were described as mean (standard deviation)
or median (interquartile range) when continuous, and N
(%) when categorical. Distributions of continuous vari-
ables were checked to determine the most appropriate
statistic to use for description in each case. Observed
agreement between unblinded and trial measurements
was assessed using a two-way mixed-effects model intra-
class correlation coefficient (ICC), mean difference and
mean absolute difference which ignored the direction of
difference. Differences were calculated as unblinded
measurement minus trial measurement. Agreement on
image usability between blinded assessors was evaluated
using binary Cohen’s kappa and observed agreement on
lesion measurement between blinded assessors was eval-
uated using two-way mixed-effects model ICC.
To repeat the trial primary analysis speed of healing
was calculated as (6-week lesion area minus baseline
Fig. 1 Using specialist software to measure a lesion’s area in the STOP GAP trial
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lesion area in cm2)/time in days. The between-arm dif-
ference in speed of healing was estimated using a normal
linear regression model with baseline lesion size and
presence of underlying systemic disease at baseline as
covariates. This analysis was first carried out using trial
measurements, to replicate the results of the STOP GAP
trial analysis [13], and then using unblinded measure-
ments only. The treatment estimates were compared
using a test of homogeneity, in which we tested the null
hypothesis that the coefficients were equal.
We then increased the observed difference between
unblinded and trial measurements (unblinded minus
trial) by multiplying it by a scale factor of (a) 2 and (b)
5, in order to investigate whether a large error or bias
would alter the findings. We did this in both treatment
groups and in the ciclosporin arm only to introduce
nondifferential and differential measurement error, re-
spectively. The ciclosporin arm was selected due to
STOP GAP specifically investigating whether ciclosporin
was superior to prednisolone. It was suspected that any
detection bias due to unblinded outcome assessment
would appear in the ‘experimental’ arm. Speed of healing
was remodelled using these altered measurements and
the results compared to the STOP GAP trial analysis
using a test of homogeneity for each comparison.
We carried out a sensitivity analysis to investigate the
effect of removing outliers. An additional exploratory
analysis was undertaken using only participants who
were assessed with blinded digital measurements in the
STOP GAP trial analysis. The aforementioned primary
analysis was repeated on this reduced population.
All analyses were performed in Stata version 14.0.
Results
Of 112 participants included in the modified intention-
to-treat population in STOP GAP, 108 (96%) had meas-
urement data at both baseline and 6 weeks, with 4 lost
to follow-up before their 6-week visit. Eighty-six (80%)
of the 108 were assessed using digital images. The pro-
portions of patients assessed using blinded and un-
blinded measurements were similar across the treatment
groups (Table 1).
Agreement between unblinded and trial measurements
was excellent at baseline, 6 weeks and when used to cal-
culate speed of healing (Table 2). Table 3 shows agree-
ment between digital image assessors on image usability
and digital measurements. There was variable agreement
between the assessors; their agreement on image usabil-
ity was poor to fair, but when they did agree on a given
image being usable, their agreement on the actual meas-
urement was excellent.
Independent, blinded digital image assessment made
no material difference to the primary outcome for the
trial with the treatment estimates and corresponding
confidence intervals for trial and unblinded measure-
ments being near identical (Table 4).
Fig. 2 Flow diagram showing criteria for choice of assessment method used in determining speed of healing in the STOP GAP trial analysis
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Increasing the magnitude of the observed difference
between unblinded and trial measurements in both
treatment arms and in the ciclosporin arm only resulted
in treatment estimates further from zero, but these did
not materially alter the conclusions from the primary
analysis in STOP GAP (Table 5).
There were three unusual observations, as shown in
Fig. 3. Participant A in the prednisolone arm had un-
blinded measurements approximately 150 cm2 larger
than their blinded measurements at both baseline and
6 weeks. Participant B, allocated to ciclosporin, had a
substantial difference between measurement methods at
6 weeks; their blinded measurement was 0.42 cm2, whilst
their unblinded measurement was 86.35 cm2. Removing
these two participants improved the agreement between
the trial and unblinded measurements (Additional file 1).
Repeating the analysis without these participants again did
not show a noticeable difference (trial measurements
used: adjusted difference = 0.04 (95% CI −0.17 to 0.25, p =
0.71), unblinded measurements used: adjusted difference
= 0.08 (95% CI −0.14 to 0.29, p = 0.47)).
Exploratory analysis was conducted on the 86 partici-
pants who were assessed using blinded measurements in
STOP GAP. There was a more noticeable difference in
Table 1 Characteristics of participants in the STOP GAP trial
Blinded measurements useda Unblinded measurements used
Characteristic Ciclosporin (n = 45) Prednisolone (n = 41) Ciclosporin (n = 12) Prednisolone (n = 10)
Age at randomisation (years)
Mean [SD] 57.4 [16.5] 52.6 [14.6] 55.4 [20.0] 47.7 [16.4]
Gender
Male 14 (31%) 18 (44%) 3 (25%) 3 (30%)
Female 31 (69%) 23 (56%) 9 (75%) 7 (70%)
Ethnicity
White 42 (93%) 41 (100%) 11 (92%) 10 (100%)
Non-White 3 (7%) 0 (0%) 1 (8%) 0 (0%)
Type of pyoderma gangrenosum
Classical 40 (89%) 35 (85%) 8 (67%) 10 (100%)
Cribriform 2 (4%) 2 (5%) 2 (17%) 0 (0%)
Peristomal 2 (4%) 2 (5%) 0 (0%) 0 (0%)
Bullous 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Unsure 1 (2%) 1 (2%) 2 (17%) 0 (0%)
Location of lesion
Arm 2 (4%) 1 (2%) 0 (0%) 0 (0%)
Leg 31 (69%) 24 (59%) 8 (67%) 8 (80%)
Other 12 (27%) 16 (39%) 4 (33%) 2 (20%)
Blinded measurements available at baseline
One assessor’s measurement available 20 (44%) 18 (44%) 0 (0%) 2 (20%)
Both assessors’ measurements available 25 (56%) 23 (56%) 1 (8%) 2 (20%)
Neither assessors’ measurements available – – 11 (92%) 6 (60%)
Blinded measurements available at 6 weeks
One assessor’s measurement available 28 (62%) 19 (46%) 2 (17%) 1 (10%)
Both assessors’ measurements available 17 (38%) 22 (54%) 1 (8%) 0 (0%)
Neither assessors’ measurements available – – 9 (75%) 9 (90%)
Time from baseline visit to ‘6-week’b follow-up visit (days)
Median (IQR) 46 (42, 49) 42 (42, 47) 49 (44, 51) 44 (41, 49)
(Min, Max) (23, 59) (19, 54) (42, 80) (40, 71)
All data are N (%) unless otherwise indicated
aFor each participant, blinded digital measurements had to be available at baseline and at 6 weeks in order for this method to be used for that participant in the
STOP GAP trial analysis
bParticipants whose lesion had healed before the scheduled 6-week visit had their visit brought forward
IQR interquartile range, SD standard deviation
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the estimated treatment effects than in the primary ana-
lysis, but there was insufficient evidence to conclude
benefit of either treatment (Additional file 2).
Discussion
Summary of main findings
In STOP GAP, unblinded physical measurements con-
sistently overestimated lesion size, but agreement be-
tween trial and unblinded measurements was still
excellent. This overestimation using unblinded measure-
ments could be explained by the approximation of the
lesion area as elliptical in shape. Our study found similar
results when using either the blinded or unblinded pri-
mary outcome; there was no evidence of detection bias,
suggesting that the use of independent, blinded digital
image assessment was not necessary in the STOP GAP
trial. Increasing the magnitude of the observed differ-
ence between unblinded and trial measurements
favoured ciclosporin over prednisolone, although preci-
sion remained insufficient to rule out benefit of either
treatment. These findings question the usefulness of
digital image assessment in a trial with an objective out-
come and where bias is not expected to be excessive.
Findings in context of previous research
A recent Cochrane review by Ndounga Diakou et al.
[11], which investigated how the blinding status of on-
site assessors affected the benefit of independent,
blinded outcome assessment, found similar conclusions.
The review found that blinded outcome assessment had
little to no impact on the treatment-effect estimates.
However, as mentioned previously Ndounga Diakou et
al. suggest that open-label trials could benefit most from
additional blinded assessment. Therefore, it is important
to note that as our findings do not appear to agree with
this notion, they may not be generalisable. Although, this
disagreement may be due to the fact that Ndounga
Diakou et al. looked at a range of studies with subjective
outcomes, whereas we investigated one trial with an
objective primary outcome.
When comparing the use of trial and unblinded mea-
surements when determining the STOP GAP trial’s pri-
mary outcome we found the estimated treatment effects
Table 2 Agreement between unblinded measurements and trial measurements
Ciclosporin (n = 57) Prednisolone (n = 51) Total (n = 108)
Lesion size at baseline (cm2)
Mean difference [SD] 4.9 [10.2] 6.7 [22.1] 5.8 [16.8]
Mean absolute difference [SD] 5.5 [9.9] 7.0 [22.0] 6.2 [16.7]
ICC (95% CI) 0.97 (0.94 to 0.99) 0.84 (0.73 to 0.91) 0.92 (0.88 to 0.95)
Lesion size at 6 weeks (cm2)
Mean difference [SD] 4.7 [12.4] 5.2 [25.4] 4.9 [19.5]
Mean absolute difference [SD] 4.8 [12.3] 5.3 [25.3] 5.0 [19.5]
ICC (95% CI) 0.92 (0.85 to 0.95) 0.76 (0.61 to 0.85) 0.83 (0.76 to 0.88)
Speed of healing (cm2/day)
Mean difference [SD] 0.00 [0.24] −0.04 [0.20] −0.02 [0.22]
Mean absolute difference [SD] 0.10 [0.21] 0.09 [0.19] 0.10 [0.20]
ICC (95% CI) 0.97 (0.95 to 0.98) 0.89 (0.82 to 0.94) 0.96 (0.94 to 0.97)
The differences between measurement methods were calculated by unblinded physical measurement – trial measurement. CI confidence interval, ICC intraclass
correlation coefficient, SD standard deviation
Table 3 Agreement between digital image assessors
Baseline (n = 112) 6 weeks (n = 108)a
Agreement on image usability
Both assessors agree on image usability 71 (63%) 58 (54%)
Cohen’s Kappa (95% CI) 0.23 (0.07 to 0.40) 0.12 (−0.04 to 0.27)
Agreement on blinded digital measurements
Both assessors’ measurements available 52 (46%) 40 (37%)
ICC of assessors’ measurements (95% CI) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)
All data are N (%) unless otherwise indicated
a4 patients were lost to follow-up (did not have a 6-week visit)
CI confidence interval, ICC intraclass correlation coefficient
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to be identical, contrary to other studies [17–19] which
have found unblinded trials often overestimate treatment
effects. However, this may be partially attributed to the
fact that our primary analysis did not directly compare
blinded versus unblinded outcome assessment; only 80%
of the trial measurements were blinded. The exploratory
analysis, using the reduced population of participants
assessed using blinded measurements, found the
treatment-effect estimate using the unblinded measure-
ments to be at least ten times larger in magnitude than
when only the blinded measurements were used. How-
ever, this analysis still resulted in the same conclusion as
our primary analysis in that digital image assessment did
not change the trial findings.
The potential for bias tends to be higher when the pri-
mary outcome is a subjective measure, such as quality of
life, rather than a clearly defined objective one [1, 5, 20,
21] such as lesion size in STOP GAP. Moreover, the
overestimation in the unblinded physical measurements
was consistent over both treatment groups rather than
biased, and was likely due to their crude nature.
Additionally, there is no recommended initial treatment
nor were there any preconceived ideas about the super-
iority of either drug due to PG being very rare. This
could explain why we observed no difference between
assessment methods, as nondifferential error can be ex-
pected, which would dilute the treatment estimates ra-
ther than introduce bias [22].
A recent study [1], which reviewed the use of digital
photographs for blinded outcome assessment in a clin-
ical trial looking at treatments for verrucae [23], found
that blinded digital image assessment did not have an
impact on the trial conclusions. Similarly, the conclu-
sions of STOP GAP would not have been altered even if
the observed difference between the unblinded and trial
measurements was increased differentially in the ciclos-
porin arm by a factor of 5. However, this may be due to
the fact that the speed of healing was already very simi-
lar between the two treatment groups in the trial, so it
would be hard for detection bias to introduce enough
variation to change the result. If the trial initially pro-
vided stronger evidence of a treatment effect, then our
study might have reached a different conclusion.
It is important to consider the cost of digital image as-
sessment, which we estimated to be £20,000, approxi-
mately 2% of the total budget for this trial. This includes
the cost of equipment and software, training of both
image assessors, travel for the specialist trainers, and
payment for all staff involved to carry out the image
processing and assessment. Alongside costs, it is also
Table 4 Speed of healing over 6 weeks by assessment method
Lesion size assessment
method
Treatment
group
Number in
group
Mean (SD) speed of
healing (cm2/day)
Difference in means
(ciclosporin –prednisolone)
Adjusted differencea
(95% CI)
p value p valueb
Trial measurements Ciclosporin 57 −0.21 (1.00) −0.074 0.003 (−0.20 to 0.21) 0.97 1.00
Prednisolone 51 −0.14 (0.42)
Unblinded measurements
only
Ciclosporin 57 −0.21 (1.00) −0.035 0.003 (−0.24 to 0.25) 0.98
Prednisolone 51 −0.18 (0.47)
aAdjusted by stratification factors baseline lesion size and presence of underlying systemic disease
bp value for test of homogeneity
Table 5 Speed of healing over 6 weeks using unblinded measurements only, with increased difference between measurements
Observed measurement
differencea increase
Treatment
group
Number in
group
Mean (SD) speed of
healing (cm2/day)
Difference in means
(ciclosporin –prednisolone)
Adjusted differenceb
(95% CI)
p value p valuec
Both treatment groups
2× Ciclosporin 57 −0.21 (1.05) 0.004 0.017 (−0.29 to 0.32) 0.91 0.93
Prednisolone 51 −0.21 (0.59)
5× Ciclosporin 57 −-0.20 (1.44) 0.122 0.115 (−0.38 to 0.61) 0.65 0.66
Prednisolone 51 −0.33 (1.11)
In ciclosporin group only
2× Ciclosporin 57 −0.21 (1.05) −0.071 0.115 (−0.12 to 0.35) 0.34 0.35
Prednisolone 51 −0.14 (0.42)
5× Ciclosporin 57 −0.20 (1.44) −0.066 0.212 (−0.17 to 0.59) 0.27 0.28
Prednisolone 51 −0.14 (0.42)
aThe differences between measurement methods were calculated by unblinded physical measurement – trial measurement
bAdjusted by stratification factors baseline lesion size and presence of underlying systemic disease
cp value for test of homogeneity between the treatment estimate and the treatment estimate from the STOP GAP trial analysis using trial measurements
(see Table 4)
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important to recognise the time involved in these pro-
cesses. For instance, whilst the unblinded assessors
found the measuring process relatively straightforward,
the blinded image assessors had difficulties initially using
the software and found the actual measurement process
to be time-consuming.
Additionally, in STOP GAP, there was a difficulty in
measuring photographs of lesions that were particularly
large or circumferential such as when stretched around
the curvature of a limb. This finding agrees with a study
[24] that compared wound measurement using two
techniques; a manual tracing process and computer soft-
ware which calculated the measurement after the wound
was photographed. The study found that as digital pho-
tographs are a 2D image attempting to capture a 3D
structure, ‘discrepancy may also occur when tracing cir-
cumferential wounds’. It can also be hard to measure
digital photographs of lesions when a participant ex-
hibits subtle symptoms, such as redness or swelling,
which can affect outcome measures. In fact, the outlying
participants referred to earlier as A and B are such cases
of this. An inspection of their digital images revealed
that participant A had a large circumferential lesion
which covered most of their forearm, whilst participant
B’s lesion was healing in patches with a large amount of
surrounding redness. It is probable that these properties
were the cause of the disparity between their blinded
and unblinded measurements.
Furthermore, blinded digital measurements were only
obtained for 80% of patients; 20% of the sample would
have had no primary outcome data if unblinded physical
measurements had not also been taken as a back-up and
so would have been excluded from the primary analysis.
An alternative method of incorporating blinding in STOP
GAP would have been to use a ‘double dummy’ design
[25], with each participant receiving one placebo and one
active treatment. However, whilst participants and asses-
sors may be blinded at baseline, this approach would not
mask the difference in side effects that would be evident a
short time after receiving either treatment. This would
have the potential to lead to unblinded participants which,
in turn, could lead to unblinded assessors. Additionally,
this design is potentially more expensive to implement
than digital image assessment. Another possible approach
to facilitate blinding could include the use of an additional
dermatologist in participant follow-up visits. This derma-
tologist would be employed purely to conduct measure-
ments, without any further participant interaction or
exposure to participant data. However, whilst this would
have avoided the complications of digital photography,
this approach may not have been feasible in a trial involv-
ing a rare disease such as the STOP GAP trial. Moreover,
the use of digital image assessment may have increased
the accuracy of the measurements as crude physical mea-
surements have been seen to overestimate wound area by
10% [26]. This is desirable regardless of the fact that the
results remained unaffected. It also enabled global assess-
ment of the lesion severity and made it possible for ex-
perts to check the diagnosis, which was important for a
rare condition that recruiting physicians rarely see.
Fig. 3 Plot of trial measurements against unblinded measurements at baseline and 6 weeks
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We found that the agreement on measurements be-
tween the two assessors was high at both baseline and
6 weeks. As blinded measurements were obtained using
computerised assessment and a clear set of instructions,
this was not unexpected. The implication from this find-
ing is that the cost of assessment could have been re-
duced by having only one assessor. However, we
observed that if this was the case and only one assessor
had been used, on average 49% of the participants would
have been assessed using blinded measurements, rather
than the 80% observed in STOP GAP. This is due to the
low agreement between assessors on image usability and
provides some justification for the use of multiple asses-
sors; if digital image assessment is seen to be an import-
ant element of the trial design to facilitate blinding, it is
vital to ensure that the majority, if not all, of the out-
come data received are of a blinded nature. Additionally,
the use of multiple assessors adds to the validity of the
measurements; if only one assessor is used and is con-
sistently measuring the images incorrectly, there would
be no verification and their measurements could cause
misleading results and conclusions to be drawn.
An additional benefit that independent, blinded digital
image assessment had on STOP GAP was that it im-
proved the credibility of the trial findings. Furthermore,
it ensured that the trial would be scored as being of high
quality in any subsequent systematic reviews [27]. Due
to blinded outcome assessment being seen as the ‘gold
standard’, researchers often strive to ensure that at least
the primary outcome is blinded. In fact, a study by
Olson et al. [28] has shown that manuscripts which re-
port on trials with some form of blinding are three times
more likely to be published than those that could have
been blinded but were not. Therefore, whilst we have
shown in this single case that blinded outcome assess-
ment did not impact on the trial results, it would be of
interest to know whether journal editors or the wider
scientific community would have accepted the findings
had blinded digital image assessment of the primary out-
come not been implemented.
Strengths and limitations
A limitation of this study was that comparing blinded
and unblinded assessment was confounded by the meas-
urement method. In order to make a direct comparison,
we would have required blinded assessors in clinics
taking physical measurements and/or unblinded asses-
sors calculating lesion area using digital images and the
specialist software. Furthermore, we were restricted by
the small dataset that we had available. As PG is a very
rare disease and our analysis was limited to 108 partici-
pants, exploring digital image assessment in this setting
should be treated as a hypothesis-generating process ra-
ther than a hypothesis-confirming one. Therefore,
caution should be taken before our results are general-
ised to other situations or disease areas. However, we
have shown that in some circumstances, blinded out-
come assessment may not be a necessity to preserve trial
quality. We understand that another constraint of our
research is that we have only investigated a single trial.
Regardless, our findings can be used together with other
studies to add to the pool of current knowledge.
One strength of this study is that our results remained
robust to a variety of assumptions. With observed differ-
ence between unblinded and trial measurements in-
creased both nondifferentially and differentially by up to
five times, our primary analysis still suggested that
blinded outcome assessment was not necessary in STOP
GAP. In fact, we found that it would require the ob-
served difference to be increased by more than 20 times
to meaningfully shift the primary outcome, which we
feel is implausible. Furthermore, two sensitivity analyses
were performed: excluding extreme observations, and an
exploratory analysis. Both analyses concluded that digital
image assessment did not have an impact on the primary
outcome. This helps to reinforce the robustness of our
results.
Conclusions
This study found that independent, blinded digital image
assessment did not meaningfully shift trial conclusions
in STOP GAP, even when large differential error was in-
troduced. An estimate suggested that the process of col-
lecting and analysing digital images cost approximately
2% of the total trial budget. Given the added accuracy,
confidence and credibility that independent image as-
sessment provided in the STOP GAP trial, we conclude
that it was worth the minimal expense. We recommend
that digital image assessment may be more useful for
easily photographed illnesses, where circumferential le-
sions are not an issue, for example. We advise that fu-
ture trials which choose to use digital image assessment
ensure they have a back-up assessment method in place
for when images fail.
Further research should explore the circumstances
where digital image assessment may be of most use
and if there are alternative, less complex ways of in-
corporating blinding in clinical trials.
Additional files
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trial measurements with outliers removed. Table showing agreement
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Additional file 2: Exploratory analysis – speed of healing over 6 weeks
by assessment method. Table showing results of exploratory analysis;
speed of healing over 6 weeks by assessment method. (DOCX 12 kb)
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